

Natasha Kekre

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1626011/natasha-kekre-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64 papers	761 citations	16 h-index	26 g-index
70 ext. papers	1,111 ext. citations	4.2 avg, IF	4.36 L-index

#	Paper	IF	Citations
64	The optimal timing of allogeneic stem cell transplantation for primary myelofibrosis.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		1
63	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.. <i>Cytotherapy</i> , 2022 ,	4.8	2
62	Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.. <i>Annals of Hematology</i> , 2022 , 1	3	
61	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.. <i>Nature Medicine</i> , 2022 ,	50.5	8
60	Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation - a retrospective analysis. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 437-442	1.6	
59	Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). <i>Blood</i> , 2021 , 138, 739-739	2.2	2
58	Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). <i>Blood</i> , 2021 , 138, 430-430	2.2	0
57	HematologistsTbarriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study. <i>Trials</i> , 2021 , 22, 230	2.8	3
56	Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial. <i>BMJ Open</i> , 2021 , 11, e043929	3	2
55	HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. <i>Blood</i> , 2021 , 138, 273-282	2.2	15
54	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021 , 39, 448-464	1.3	0
53	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 68.e1-68.e9		4
52	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1006-1012	4.4	5
51	Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy. <i>BMJ Open</i> , 2021 , 11, e046707	3	0
50	Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials. <i>Research Involvement and Engagement</i> , 2020 , 6, 61	4.4	3
49	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. <i>BMJ Open</i> , 2020 , 10, e034714	3	5
48	Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1298-1302	4.7	6

47	A Rapid and Sensitive Nucleic Acid Amplification Technique for Screening of Cell Therapy Products. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020 , 17, 393-399	6.4	7
46	Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1454-1456	4.4	1
45	Surgical Site Infection Affects Length of Stay After Complex Head and Neck Procedures. <i>Laryngoscope</i> , 2020 , 130, E837-E842	3.6	4
44	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. <i>Blood</i> , 2020 , 136, 16-16	2.2	
43	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020 , 136, 21-22	2.2	
42	Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL). <i>Blood</i> , 2020 , 136, 49-49	2.2	30
41	Efficacy, Safety, and Practicality of Tacrolimus Monitoring after Bone Marrow Transplant: Assessment of a Change in Practice. <i>Canadian Journal of Hospital Pharmacy</i> , 2020 , 73, 37-44	0.5	
40	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
39	Building Canadian capacity for CAR-T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study. <i>British Journal of Haematology</i> , 2020 , 191, e14-e19	4.5	1
38	Alternative donor transplantation for acute myeloid leukemia in patients aged 50 years: young HLA-matched unrelated or haploidentical donor?. <i>Haematologica</i> , 2020 , 105, 407-413	6.6	12
37	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2398-2407	4.7	8
36	Venous thromboembolism incidence in hematologic malignancies. <i>Blood Reviews</i> , 2019 , 33, 24-32	11.1	29
35	The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. <i>Hematology, Transfusion and Cell Therapy</i> , 2019 , 41, 285-291	1.6	2
34	Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019 , 14, 179-187	6.4	11
33	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , 2019 , 134, 3263-3263	2.2	
32	Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. <i>Transfusion Medicine Reviews</i> , 2019 , 33, 98-110	7.4	66
31	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2199-2204	7.8	24
30	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019 , 3, 3123-3131	7.8	18

29	Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 68-72	2	
28	Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. <i>Blood Cancer Journal</i> , 2018 , 8, 14	7	3
27	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2466-2470	4.7	5
26	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018 , 132, 817-817	2.2	
25	Complications and Toxicities Associated with Autologous Stem Cell Transplantation for Severe Autoimmune Diseases: Single Center Experience. <i>Blood</i> , 2018 , 132, 4624-4624	2.2	
24	Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?. <i>Blood</i> , 2018 , 132, 5159-5159	2.2	
23	Provincial Disparities in Access to Allogeneic Transplant in Canada. <i>Blood</i> , 2018 , 132, 4742-4742	2.2	
22	Natural Killer Cell IFN γ Secretion is Profoundly Suppressed Following Colorectal Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3747-3754	3.1	4.1
21	Diagnosis and treatment of acute graft-versus-host disease 2017 , 324-333		1
20	Venous thromboembolism is associated with graft--host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017 , 102, 1185-1191	6.6	18
19	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017 , 102, 1291-1298	6.6	26
18	Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 2096-2101	4.7	22
17	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2017 , 7, e019321	3	14
16	ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. <i>Blood Advances</i> , 2017 , 1, 573-576	7.8	19
15	Cord blood versus haploidentical stem cell transplantation for hematological malignancies. <i>Seminars in Hematology</i> , 2016 , 53, 98-102	4	12
14	Emerging drugs for graft-versus-host disease. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 209-18	3.7	5
13	Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 123-30	7.1	6
12	A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4519-4519	2.2	0

11	Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 5782-5782	2.2	0
10	Impact of HLA-Mismatch in Unrelated Donor Hematopoietic Stem Cell Transplantation: A Meta-Analysis. <i>American Journal of Hematology</i> , 2016 , 91, 551-5	7.1	20
9	Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1416-1423	4.7	56
8	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1808-1815	4.7	18
7	Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. <i>Blood</i> , 2014 , 124, 334-43	2.2	103
6	Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1719-24	4.7	32
5	Modelling improvements in cell yield of banked umbilical cord blood and the impact on availability of donor units for transplantation into adults. <i>Stem Cells International</i> , 2013 , 2013, 124834	5	1
4	The impact of prolonged storage of red blood cells on cancer survival. <i>PLoS ONE</i> , 2013 , 8, e68820	3.7	15
3	Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012 , 52, 2049-54	2.9	9
2	Spontaneous tumour lysis syndrome. <i>Cmaj</i> , 2012 , 184, 913-6	3.5	45
1	Storage time of transfused red blood cells and impact on clinical outcomes in hematopoietic stem cell transplantation. <i>Transfusion</i> , 2011 , 51, 2488-94	2.9	15